Helicobacter pylori: Review of triple, dual, 7-day, and other treatment strategies

Since the identification of Helicobacter pylori in 1983, the pathogen has become the dominant focus of the investigation of peptic ulceration and gastric carcinoma. During the last 7 years, the efficacy of multiple antimicrobial regimens in curing this infection has been examined. More recently, newer treatment approaches-such as dual therapy and 7-day regimens- have shown a high degree of success and have the potential of improving compliance. Vaccines to prevent acquisition of H pylori, and perhaps clear the organism in infected patients, are under development. Still to be determined are the least expensive, most efficacious, and well-tolerated regimen, and optimal length of treatment.